Systemic sclerosis (SSc) is a heterogeneous autoimmune disease associated with several antinuclear autoantibodies useful to diagnosis and prognosis. The aim of the present multicentric study was to determine the clinical relevance of antifibrillarin autoantibodies (AFA) in patients with SSc. The clinical features of 37 patients with SSc positive for AFA (AFA+) and 139 SSc patients without AFA (AFAÀ) were collected retrospectively from medical records to enable a comparison between AFAÀ and AFA+ patients. Antifibrillarin autoantibodies were screened by an indirect immunofluorescence technique using HEp2 cells and identified by an in-house Western blot technique and/or an EliA test. Comparing AFA+ and AFAÀ patients, AFA+ patients were significantly younger at disease onset (36.9 versus 42.9; P = 0.02), more frequently male (P = 0.02) and of Afro-Caribbean descent (65% versus 7.7%; P < 0.001). At diagnosis, the Rodnan skin score evaluating the cutaneous manifestations was higher (13.3 versus 8.7; P = 0.01) and myositis was also more common in the AFA+ group (31.4% versus 12.2%; P < 0.01). Patients with AFA+ were not associated with diffuse cutaneous SSc or with lung involvement and no difference in survival was observed. Antifibrillarin autoantibodies are associated with patients of Afro-Caribbean origin and can identify patients with SSc who are younger at disease onset and display a higher prevalence of myositis.
Introduction
Systemic sclerosis (SSc) is a heterogeneous connective tissue disease characterized by dysfunction of the endothelium, excessive collagen production due to dysregulation of fibroblasts and altered immune system regulation with the production of SSc-specific autoantibodies [1] [2] [3] . In 2001, Leroy and Medsger proposed a classification that takes into account the immunological profile of the patients [4] [5] [6] . In 2013, the American College of Rheumatology/European League against Rheumatism (ACR/EULAR) criteria included a number of SSc-related antinuclear autoantibodies (ANA) such as antitopoisomerase I (Scl-70), anticentromere and anti-RNA polymerase III autoantibodies [7] . Testing for additional more recent SSc-related autoantibodies such as anti-Th/To and anti-U3-RNP namely fibrillarin autoantibodies (AFA) has been suggested [7] , and several studies support the relevance of subgrouping patients on the basis of the type of autoantibodies present in their sera [8] [9] [10] . More than 90% of patients with SSc have ANA [11] [12] [13] [14] , and associations between some of them, such as anticentromere and antitopoisomerase I, and specific clinical characteristics have been described [11, [15] [16] [17] . However few studies have evaluated the clinical interest of more recent SSc-related ANA-like AFA [12, 18] . Indeed, as anticentromere and antitopoisomerase I autoantibodies, AFA might also be a good diagnostic and/or predictive marker, especially in patients who do not display the classical SSc-related ANA. Up to date, AFA have been found in 7-18% of patients with SSc, with differences across ethnic groups ranging from 0% in an Italian population to 50% in an African American population [12, [18] [19] [20] [21] [22] . To further determine the clinical relevance of AFA in French patients with SSc, we studied the relationship between their presence and particular clinical characteristics in a population of patients suffering from SSc and followed in three national centers.
Materials and methods
Patients and study design. Thirty-seven patients with scleroderma displaying positive AFA (AFA+) from three centers (Saint-Antoine Hospital, Paris; Kremlin-Bicêtre Hospital, Kremlin-Bicêtre; and Hospices Civils de Lyon, Lyon, France) were included in this study. The prevalence of AFA antibodies in patients with SSc was 7-11% in our three centers. During the same period of recruitment, 139 patients with scleroderma but negative for AFA (AFAÀ) were also included as controls. All patients, followed in internal medicine departments, fulfilled both Leroy's criteria for classification of the disease and the ACR criteria. French observational studies from data obtained from a retrospective study, without any additional therapy or monitoring procedure, do not need informed consent from the patients as autoantibodies were analysed as part of their diagnosis investigation. Patient records and information were anonymized and de-identified prior to analysis. The study was approved by the Research and the Ethical Committees of the Hospices Civils de Lyon.
Data collection. All clinical and demographic features were collected retrospectively, mainly through a review of the patients' medical records. To minimize missing data, general practitioners were contacted, particularly in the case of patients with no follow-up. The clinical features of patients were reviewed first of all at the time of serum collection. Age at symptom onset was defined as the age the first symptoms attributable to SSc developed. According to Leroy [23] , diffuse skin involvement was defined by skin tightening proximal to the elbows or knees or distal to them, and limited SSc was defined as the form only affecting the fingers, hands and forearms distal to the elbows and distal to the knees. The Rodnan skin score [24] was also calculated to improve skin evaluations. Two aspects of skeletal muscle involvement, myalgia and myositis, were also taken into account and followed. Myositis was determined by the presence of proximal muscle weakness with muscle involvement observed on an electromyography, MRI or biopsy [25, 26] . Lung involvement was defined using pulmonary function tests and highresolution computed tomography (HRCT). Interstitial lung disease was defined on HRCT from images of ground glass opacifications, reticular opacities, traction bronchiectasis and/or honeycombing [27, 28] . Pulmonary arterial hypertension (PAH) was evaluated from an echocardiogram (mean pulmonary artery pressure (PAPS) >40 mmHg) and in some cases following catheterization to determine rightside cardiac pressure (PAP ≥25 mmHg) [29] . Restrictive lung disease was characterized by reduced total lung capacity or forced vital capacity and confirmed whether both the forced vital capacity and total lung capacity were lower than <80% of the predicted value.
The follow-up period was 62 months, and at the end of this follow-up period, several criteria were examined, including death, increasing interstitial lung disease (reduction in total lung capacity or forced vital capacity by >10% compared to baseline) and the onset of PAH.
Screening and identification methods of AFA and other ANA. Antifibrillarin antibodies screening: AFA were screened by indirect immunofluorescence technique (IIF) using HEp-2 cells (in-house method and Kallestad, BioRad, Marnes La Coquette, France). The presence of AFA was suspected when there was a characteristic clumpy nucleolar and coilin body pattern of staining in interphase cells and a staining of fibrillarin in metaphase cells, as previously described [12, 20] (Fig. 1) . Indeed, AFA, also referred to as anti-U3-RNP antibodies, target a component of 34 kDa in the small nucleolar ribonucleoprotein involved in pre-RNA processing that is precisely localized in the fibrillar region of the nucleolus. Titres of ANA were considered to be positive when equal or superior to 1:80.
Antifibrillarin antibodies identification: The presence of AFA was confirmed by an in-house Western blot technique and/or an EliA test.
In-house Western blot technique. Antigen preparation from liver homogenates: Rat livers from male Wistar rats (Charles River, Saint Germain sur l'Arbresle, France) were homogenized in 10 mM Tris, 250 mM sucrose and 1 mM 4-(2-aminoethyl) benzenesulphonyl fluoride buffer, using a Dounce apparatus. Nuclear fractions were then obtained after sucrose gradient density ultracentrifugation, as previously described [30] . Four hundred lg of nuclear proteins diluted in 90 ll phosphate buffer saline was then treated with 10 ll S1 nuclease (GE Healthcare Velisy-Villacoublay, France). The proteins were then precipitated using a 2-D clean-up kit from GE Healthcare, according to the manufacturer's instructions. The aliquots were stored at À80°C until use. Rats were maintained in the University Pierre and Marie Curie Paris6 animal facility according to the rules enforced by the Institutional Animal Care and Use Committee, in EOPS conditions. The animal facility institutional agreement number is B75-12-01.
Electrophoresis and immunoblotting. Nuclear antigen was first denatured in Tris 50 mM buffer, containing 20 g/l sodium dodecyl sulphate, 1 ml/L 2-mercaptoethanol, 90 ml glycerol and 0.002% w/v pyronine before resolution on 10% polyacrylamide separating gels, and electrophoretic transfer to a nitrocellulose membrane for 2 h at 60V (Bio-Rad, Hercules, CA, USA) according to the protocol described by Towbin [31] . The nitrocellulose filter was probed with sera diluted at 1:100, including a positive control for AFA, and then incubated with 1:500 diluted horseradish peroxidase-conjugated anti-human IgG (BioRad). The presence of AFA was revealed by 4-chloro 1-naphthol with 1% hydrogen peroxide. A stained band at 36 kDa corresponded to rat fibrillarin (Fig. 2) .
EliA test. AFA were also measured using an enzyme immunoassay with a fluorescent end point namely EliA test on UniCAP â 100 according to the manufacturer's instructions (PHADIA SAS, Thermo Fisher Scientific, SaintQuentin en Yvelines, France). ELiA fibrillarin wells were coated with full-length recombinant human fibrillarin produced in a baculovirus/insect cell system. The cut-off value of this method is 10 UR/ml [32] .
Other ANA screening and identification: Anticentromere antibodies were detected by IIF using HEp-2 cells (inhouse technique and Kallestad; Bio-Rad), while antitopoisomerase I and anti-U1-RNP were detected using a multiplex testing platform (BioPlex 2200, Bio-Rad, Marnes-la-Coquette, France), PM/Scl by dot-blot (Blue dot 8 TM , Diasorin, Antony, France) and anti-RNA polymerase III by ELISA (Quanta lite TM RNA Pol III, Inova diagnostic, Instrumentation Laboratory, Le Pr e Saint Gervais, France), according to the manufacturer instructions.
Statistical analysis. To compare the two groups and the frequencies of criteria of interest, Chi 2 test, or if necessary Fisher test, was used for proportions and Student's t-test for averages. P < 0.05 was taken to indicate statistical significance. Excel, Biostatgv software and XLSTAT 2013 systems were used for calculations. Because some manifestations of SSc, such as pulmonary or muscle involvement, may change during the course of the disease, these factors were adjusted using a logistic regression on disease duration to render the groups comparable and to limit their impact as confounding factors. We thus calculated the adjusted P values for the time-dependent characteristics, reducing the potential bias resulting from a comparison of two groups (AFA+ and AFAÀ) with different disease durations.
Results

Demography and population characteristics
As shown in Table 1 , the group of 37 AFA+ patients were younger at disease onset (36.9 versus 42.9 years; P = 0.02) and were more frequently male (32% versus 11.5%; P = 0.02) when compared to the 139 AFAÀ patients from the cohort used here as negative controls.
In the AFA+ group, 65% of patients were of AfroCaribbean descent in comparison with 7.7% in the AFAÀ group (P < 0.001). There was no significant difference between the two groups in terms of Asian (0% in the AFA+ group versus 3.1% in the AFAÀ group; P = 1), Maghreb (20% versus 9.2%; P = 0.23) or Iran origins (0% versus 0.8%; P = 1), while 79% in the AFAÀ group were of Caucasian origin (15% in the AFA+ group, P < 0.001).
Disease duration corresponding to the period between appearance of the first symptoms of SSc and the serum collection was 9.7 years in the AFA+ group versus 18.8 years in the AFAÀ group (P < 0.001). ........................................................................................................................................................... 
....
Clinical manifestations
Clinical manifestations were recorded for both groups and were adjusted for disease duration of 10 years. The most frequent subset of cutaneous involvement in the AFAÀ group was the limited cutaneous form (66.2%). The diffuse cutaneous form was more common in the AFA+ than in the AFAÀ group (50% versus 33.8%), but this difference did not reach significance (P = 0.08) ( Table 2) . However, the Rodnan-modified skin score was significantly higher for patients in the AFA+ group in comparison with the AFAÀ group (13.3 versus 8.7; P = 0.013). Among the AFAÀ patients, 29.6% suffered from restrictive lung disease, 51.1% from interstitial lung disease and 5.8% from PAH, but the frequency of these associated-disease was not statistically different in the group of AFA+ patients, in whom 35.5% were found to be affected by restrictive lung disease (P = 0.15), 38.2% by interstitial lung disease (P = 0.96) and 8.6% by PAH (P = 0.6) ( Table 2) .
Myositis was more common in AFA+ than in AFAÀ patients (31.4% versus 12.2%; P < 0.01), and within the AFA+ subgroup of patients with diffuse cutaneous, 50% had myositis versus 14% in the AFA+ subgroup of patients with limited cutaneous form.
Patients were examined after a follow-up period of 62 months after antibody analysis and discovery (Table 3) . There were no significant differences between the two groups regarding lung involvement, PAH, interstitial lung disease or interstitial lung disease worsening. At the end of the follow-up period, five AFA+ patients (14.7%) versus 18 (16.2%) in the AFAÀ group had died, and no significant difference in survival was found after adjustment to disease duration (P = 0.34).
Characteristic IIF pattern of AFA and frequencies of other scleroderma-specific autoantibodies
In the AFA+ population, all patients had positive ANA with a typical nucleolar clumpy pattern ( Fig. 1 ) with titres higher than 1:640, except one with 1:320. Two patients with AFA also displayed anti-RNA polymerase III autoantibodies and one anticentromere autoantibody.
In the AFA-population, 127 patients (91%) had positive ANA. Among them, 102 patients displayed 
Discussion
The present report determines the clinical relevance of AFA antibodies in patients with SSc. The observed rate of 7-11% in our cohorts from three national centers argues in favour of the detection of these autoantibodies in patients with suspected SSc, especially in patients with a typical nucleolar pattern of ANA and with no other specific scleroderma autoantibodies. This frequency is similar to what was found in previous studies with a prevalence of AFA+ between 4% and 14% according to region and ethnic group [12, 21, 33] . The variability observed could also be due to the different techniques of detection. In the present study, we gave much attention to the validation of the tests and found that both in-house Western blot using rat liver and EliA technique using human recombinant antigen gave the same analytical performances (data not shown).
Our data clearly showed that the presence of AFA was more common in patients of Afro-Caribbean descent, results which are in line with previous studies [17, 33, 34] . Categorizing patients by ethnic origin in biomedical research is currently controversial [35] . There is no doubt that knowledge of the geographical origin of a patient may in some cases points to the cause of a disease (such as familial Mediterranean fever, haemochromatosis, some autoimmune diseases), but the use of ethnicity needs to be modulated by factors such as the environment, socioeconomic conditions and culture. The danger of categorizing patients clinically based on their ethnic origins have indeed been reported by some authors, who have usually suggested that these categories should preferably be based on genetic differences, to prevent any racial bias [36] . Interestingly, it has been shown that the presence of AFA is associated with the HLA DRB1*0804 allele for AfroCaribbean patients with SSc [18] .
The other demographic characteristics of the patients are also in line with previous studies [17, 33, 37] ; AFA+ group was younger at disease onset, was more frequently male and exhibited shorter disease duration.
We did not observe significantly more patients with diffuse cutaneous involvement in the AFA+ group, in contrast to preceding studies [2, 12, 16, 38] . Only a trend was found for more diffuse cutaneous form in the AFA+ group compared with the AFAÀ group, suggesting that our studied group was eventually not large enough to see a difference. However, the modified Rodnan skin thickness score was greater in AFA+ than in AFAÀ patients, indicating more severe cutaneous involvement in AFA+ patients, independently of the degree of thickening.
Among AFA+ patients, 31.4% had myositis versus 12.2% in AFAÀ group. These results are in line with a previous study, showing also a higher prevalence of myositis in AFA+ patients (25%) in comparison with AFAÀ patients (14%) [33] . Another study showed that the prevalence of myositis in AFA+ patients could even reach 54% within the diffuse cutaneous subgroup [12] . There was no difference in terms of lung involvement between the two patient groups, regarding interstitial lung disease, restrictive lung disease or pulmonary hypertension. Lung involvement is known to be a major cause of death in patients with SSc [1, 2, 39, 40] , but opposite results have been reported regarding the relationship between the degree of interstitial lung disease involvement or PAH and the presence of AFA. Some have reported a higher incidence of PAH in patients with AFA [8, 12] , whereas others found more frequent interstitial lung disease [41] , and/or similar frequency of lung involvement [9] . In our study, at the end of the follow-up period, no significant difference between the two groups was found concerning the percentage of PAH, restrictive lung disease, interstitial lung disease or the worsening of interstitial lung disease. The lack of difference in lung involvement between the groups is consistent with the similar survival rate of the patients.
Additional clinical parameters, such as the degree or extent of damage to heart muscle tissues or the effect of angiotensin-converting enzyme on renal function [40, [42] [43] [44] , would have also been of interest to complete these observations and could be addressed in a future study.
Conclusion
Our data confirm that AFA have clinical relevance in both the diagnosis and prognosis of SSc patients. Although with a low frequency, AFA are useful for SSc diagnosis because they were found alone in 95% of cases. Their incidence is strongly associated with Afro-Caribbean descent, a higher risk to develop myositis, severe cutaneous involvement and disability. Patients with AFA are younger at disease onset in comparison with other patients with SSc, but their survival is comparable. This study reinforces the notion that both antibodies and clinical features are essential for classifying patients with SSc in a pragmatic manner, providing support to diagnosis, monitoring and treatment. Like antitopoisomerase I and anticentromere antibodies, AFA should thus be added to the list of the relevant routine biological markers contributing to the diagnosis and the classification of this heterogeneous disease.
